Related references
Note: Only part of the references are listed.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Amir Sabet et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function
Daniel I. Chasman et al.
HUMAN MOLECULAR GENETICS (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Pharmacokinetics of L-Arginine in Adults with Moderately Severe Malaria
Tsin W. Yeo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes
Sibel Kantarci et al.
NATURE GENETICS (2007)
Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
Edgar J. Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues
M Melis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Share Paper
